When a medicine's effect weakens, searching only for a stronger medicine is not enough. Preventing infection, testing at the right time and appropriate treatment are needed together.
Why in the News
In an expert discussion published on 2 September 2026, Dr Kamini Walia of the Indian Council of Medical Research explained drug-resistant infections by connecting them with hospitals' prevention and diagnostic systems. The discussion's basis was a multi-hospital study published on 30 July 2026. Do not take it as a study first released in September or a population survey of the whole of India.
Key Facts
The study's basis: 1,59,336 admitted patients were followed in 20 tertiary hospitals from April 2022 to April 2025. Of these, 26,213 had a recorded infection from the study's four major Gram-negative bacteria. The two numbers do not describe the size of one same group.
The proportion of resistance: 61.1 per cent of these 26,213 patients had a carbapenem-resistant infection. Carbapenems are a class of antibiotics used in treating serious bacterial infections. This proportion cannot be applied to all Indians or to every hospital.
The outcome signal: in the study, the resistant group of all four bacteria showed a higher relative risk of death and antibiotic costs 1.1-2 times higher. The cost was only of medicines at Jan Aushadhi rates, not the full hospital bill.
Why Is the Problem Not Just Taking More Medicine?
The spread of infection: in hospitals, hand hygiene, the safe use of equipment and cleaning the environment are important in stopping the spread of resistant bacteria. If infection falls, the need for medicine will also fall.
Delay in diagnosis: timely identification of the bacterium and its sensitivity can improve the choice of treatment. Testing, clinical judgement and the availability of medicine should work together.
Responsible use and access: antimicrobial stewardship means an organised system of choosing the right medicine and duration according to clinical need. While stopping unnecessary use, a needy patient's access to an effective medicine must also remain.
Analysis and Way Forward
This is an observational study, in which all causes such as disease severity and the timing of correct treatment could not be fully adjusted. So the association between resistance and higher death is important, but it does not prove a single cause for every additional death. Differences seen between newer treatments should not be turned into any medicine's universal superiority or an individual prescription. Policy should develop monitoring that connects laboratory results with patients' treatment and outcomes. Infection prevention, clinical training and diagnostic capacity should get as much importance as the search for new medicines. In the broader One Health view, also look at the links between humans, animals and the environment; this hospital study alone does not measure the risk of every sector.
The Difference in Concept
The proportion of resistance recorded in hospitals is not a national prevalence rate. An association is not full proof of a cause; antibiotic cost is not total treatment cost.
Mains Perspective
The health system in GS-II and biotechnology in GS-III. Connect surveillance, infection control, access to medicine and responsible use in a shared policy.
Answer Outline
Introduction: The definition of resistance in pathogens.
Main Body: The spread of infection and diagnosis; responsible use and equitable access.
Conclusion: Surveillance, prevention and One Health coordination.
Sources
- The original research: published 30 July 2026; the method, results and limitations
- The expert discussion of 2 September, updated 8 September: an explanation of the study
- WHO's factual background: the definition of AMR and consolidated measures
Remember: resistance occurs in pathogens; hospital-based research does not state a national prevalence rate or any medicine's universal superiority.